The strength of association between pre-and post-booster BNT162b2 anti-SARS-CoV-2 antibodies levels depends on the immunoassay
ABSTRACT: Objectives: Reliable evidence suggests that anticipating the humoral response to coronavirus disease 2019 (COVID-19) vaccines is essential for predicting their clinical effectiveness. In this work, we sought to determine the extent to which the response of anti-SARS-CoV-2 antibodies BNT162...
| Main Authors: | , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Elsevier
2021-10-01
|
| Series: | International Journal of Infectious Diseases |
| Subjects: | |
| Online Access: | http://www.sciencedirect.com/science/article/pii/S1201971221006937 |
| _version_ | 1819121564718727168 |
|---|---|
| author | Gian Luca Salvagno Brandon M. Henry Giuseppe Lippi |
| author_facet | Gian Luca Salvagno Brandon M. Henry Giuseppe Lippi |
| author_sort | Gian Luca Salvagno |
| collection | DOAJ |
| description | ABSTRACT: Objectives: Reliable evidence suggests that anticipating the humoral response to coronavirus disease 2019 (COVID-19) vaccines is essential for predicting their clinical effectiveness. In this work, we sought to determine the extent to which the response of anti-SARS-CoV-2 antibodies BNT162b2 booster measured with four different commercial immunoassays could be predicted after initial homologous vaccination.Methods: This observational study enrolled 181 SARS-CoV-2 baseline seronegative healthcare workers (mean age 42±13 years; 59.7% females), who received two doses of the BNT162b2 vaccine. Antibodies levels were assessed with Roche Elecsys Anti-SARS-CoV-2 S, ACCESS SARS-CoV-2 IgG II, Snibe S-RBD IgG, and LIAISON SARS-CoV-2 TrimericS IgG. The correlation of anti-SARS-CoV-2 serum antibodies 21 days after the first vaccine dose and 30 days after the second dose was assessed with Pearson's test.Results: A significant correlation was found between serum anti-SARS-CoV-2 antibodies levels after the first (T1) and second (T2) BNT162b2 vaccine dose with all immunoassays, though the strength of such association depended on the immunoassay. Briefly, the highest correlation was found for LIAISON SARS-CoV-2 TrimericS IgG (r=0.71), followed by ACCESS SARS-CoV-2 IgG II (r=0.65), Snibe S-RBD IgG (r=0.52), and then Roche Elecsys Anti-SARS-CoV-2 S (r=0.40).Conclusion: The value of predicting post-booster values of anti-SARS-CoV-2 antibodies levels from pre-booster levels significantly depends on the immunoassay used. |
| first_indexed | 2024-12-22T06:38:34Z |
| format | Article |
| id | doaj.art-a0df017b45e244c0a0cbd40642ba288a |
| institution | Directory Open Access Journal |
| issn | 1201-9712 |
| language | English |
| last_indexed | 2024-12-22T06:38:34Z |
| publishDate | 2021-10-01 |
| publisher | Elsevier |
| record_format | Article |
| series | International Journal of Infectious Diseases |
| spelling | doaj.art-a0df017b45e244c0a0cbd40642ba288a2022-12-21T18:35:30ZengElsevierInternational Journal of Infectious Diseases1201-97122021-10-011116567The strength of association between pre-and post-booster BNT162b2 anti-SARS-CoV-2 antibodies levels depends on the immunoassayGian Luca Salvagno0Brandon M. Henry1Giuseppe Lippi2Section of Clinical Biochemistry, University of Verona, Verona, Italy; Service of Laboratory Medicine, Pederzoli Hospital, Peschiera del Garda, ItalyThe Heart Institute, Cincinnati Children's Hospital Medical Center, Cincinnati, OH, USASection of Clinical Biochemistry, University of Verona, Verona, Italy; Corresponding author: Giuseppe Lippi, Section of Clinical Biochemistry University Hospital of Verona, Piazzale L.A. Scuro, 10, 37134 Verona Italy, Tel. 0039-045-8122970, Fax. 0039-045-8124308ABSTRACT: Objectives: Reliable evidence suggests that anticipating the humoral response to coronavirus disease 2019 (COVID-19) vaccines is essential for predicting their clinical effectiveness. In this work, we sought to determine the extent to which the response of anti-SARS-CoV-2 antibodies BNT162b2 booster measured with four different commercial immunoassays could be predicted after initial homologous vaccination.Methods: This observational study enrolled 181 SARS-CoV-2 baseline seronegative healthcare workers (mean age 42±13 years; 59.7% females), who received two doses of the BNT162b2 vaccine. Antibodies levels were assessed with Roche Elecsys Anti-SARS-CoV-2 S, ACCESS SARS-CoV-2 IgG II, Snibe S-RBD IgG, and LIAISON SARS-CoV-2 TrimericS IgG. The correlation of anti-SARS-CoV-2 serum antibodies 21 days after the first vaccine dose and 30 days after the second dose was assessed with Pearson's test.Results: A significant correlation was found between serum anti-SARS-CoV-2 antibodies levels after the first (T1) and second (T2) BNT162b2 vaccine dose with all immunoassays, though the strength of such association depended on the immunoassay. Briefly, the highest correlation was found for LIAISON SARS-CoV-2 TrimericS IgG (r=0.71), followed by ACCESS SARS-CoV-2 IgG II (r=0.65), Snibe S-RBD IgG (r=0.52), and then Roche Elecsys Anti-SARS-CoV-2 S (r=0.40).Conclusion: The value of predicting post-booster values of anti-SARS-CoV-2 antibodies levels from pre-booster levels significantly depends on the immunoassay used.http://www.sciencedirect.com/science/article/pii/S1201971221006937SARS-CoV-2COVID-19VaccineImmunoassayAntibodies |
| spellingShingle | Gian Luca Salvagno Brandon M. Henry Giuseppe Lippi The strength of association between pre-and post-booster BNT162b2 anti-SARS-CoV-2 antibodies levels depends on the immunoassay International Journal of Infectious Diseases SARS-CoV-2 COVID-19 Vaccine Immunoassay Antibodies |
| title | The strength of association between pre-and post-booster BNT162b2 anti-SARS-CoV-2 antibodies levels depends on the immunoassay |
| title_full | The strength of association between pre-and post-booster BNT162b2 anti-SARS-CoV-2 antibodies levels depends on the immunoassay |
| title_fullStr | The strength of association between pre-and post-booster BNT162b2 anti-SARS-CoV-2 antibodies levels depends on the immunoassay |
| title_full_unstemmed | The strength of association between pre-and post-booster BNT162b2 anti-SARS-CoV-2 antibodies levels depends on the immunoassay |
| title_short | The strength of association between pre-and post-booster BNT162b2 anti-SARS-CoV-2 antibodies levels depends on the immunoassay |
| title_sort | strength of association between pre and post booster bnt162b2 anti sars cov 2 antibodies levels depends on the immunoassay |
| topic | SARS-CoV-2 COVID-19 Vaccine Immunoassay Antibodies |
| url | http://www.sciencedirect.com/science/article/pii/S1201971221006937 |
| work_keys_str_mv | AT gianlucasalvagno thestrengthofassociationbetweenpreandpostboosterbnt162b2antisarscov2antibodieslevelsdependsontheimmunoassay AT brandonmhenry thestrengthofassociationbetweenpreandpostboosterbnt162b2antisarscov2antibodieslevelsdependsontheimmunoassay AT giuseppelippi thestrengthofassociationbetweenpreandpostboosterbnt162b2antisarscov2antibodieslevelsdependsontheimmunoassay AT gianlucasalvagno strengthofassociationbetweenpreandpostboosterbnt162b2antisarscov2antibodieslevelsdependsontheimmunoassay AT brandonmhenry strengthofassociationbetweenpreandpostboosterbnt162b2antisarscov2antibodieslevelsdependsontheimmunoassay AT giuseppelippi strengthofassociationbetweenpreandpostboosterbnt162b2antisarscov2antibodieslevelsdependsontheimmunoassay |